[{"id":"1b500ef1-eb4a-46f0-934a-47ef87d67f43","acronym":"","url":"https://clinicaltrials.gov/study/NCT03098160","created_at":"2021-01-18T15:15:55.114Z","updated_at":"2024-07-02T16:37:16.776Z","phase":"Phase 1","brief_title":"Immunotherapy Study of Evofosfamide in Combination With Ipilimumab","source_id_and_acronym":"NCT03098160","lead_sponsor":"Threshold Pharmaceuticals","biomarkers":" PD-L1 • IL2","pipe":"","alterations":" ","tags":["PD-L1 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • evofosfamide (IMGS-101)"],"overall_status":"Unknown status","enrollment":" Enrollment 69","initiation":"Initiation: 05/10/2017","start_date":" 05/10/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2017-10-30"}]